Daniel Geffken

Daniel Geffken is a proven leader of life science companies with more than 30 years of experience steering strategy, finance and operations across all stages of the corporate life cycle. As Co-founder and Managing Director of Danforth Advisors, he leads a team of more than 90 consultants in strategic CFO advisory, accounting and operational support for over 100 clients, ranging from life science start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and executive-level advisor to numerous companies, including Apellis Pharmaceuticals, Cabaletta Bio, , Cidara Therapeutics, Editas Medicine, Homology Medicines, Promedior, ProMIS Neurosciences and Stealth BioTherapeutics.

Over the course of his career, Daniel has raised nearly $2 billion in equity and debt securities for life science companies. Among his pre-Danforth roles, he served as CFO of Transkaryotic Therapies, where he negotiated and closed five equity transactions totaling $600 million – including the largest private placement in biotechnology history at the time. Daniel has been a board member and chairman of audit and compensation committees of both public and private life science companies, including Windtree Therapeutics. He holds a BS from The Wharton School, University of Pennsylvania, and a MBA from Harvard Business School.